• 1
    Hanafiah KM, Groeger J, Flaxman AD, Wiersman ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology 2013;57:1333-1342.
  • 2
    Hutin Y, Kitler ME, Dore GJ, Perz JF, Armstrong GL, Dusheiko G, et al. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20-29.
  • 3
    Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81.
  • 4
    Mathers B, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372:1733-1745.
  • 5
    Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-583.
  • 6
    United Nations Office on Drugs and Crime. HIV prevention, treatment and care in prisons and other closed settings: a comprehensive package of interventions. United Nations Office on Drugs and Crime; 2012.
  • 7
    Dolan K, Kite B, Black E, Aceijas C, Stimson GV. HIV in prison in low-income and middle-income countries. Lancet Infect Dis 2007;7:32-41.
  • 8
    Hayashi K, Milloy MJ, Fairbairn N, Kaplan K, Suwannawong P, Lai C, et al. Incarceration experiences among a community-recruited sample of injection drug users in Bangkok, Thailand. BMC Public Health 2009;9.
  • 9
    Kinner SA, Jenkinson R, Gouillou M, Milloy MJ. High-risk drug-use practices among a large sample of Australian prisoners. Drug Alcohol Depend 2012;126:156-160.
  • 10
    Pollini RA, Alvelais J, Gallardo M, Vera A, Lozada R, Magis-Rodriquez C, et al. The harm inside: injection during incarceration among male injection drug users in Tijuana, Mexico. Drug Alcohol Depend 2009;103:52-58.
  • 11
    Post JJ, Dolan K, Whybin LR, Carter IW, Haber P, Lloyd A. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Med J Aust 2001;174:183-184.
  • 12
    Tsang TH, Horowitz E, Vugia DC. Transmission of hepatitis C through tattooing in a United States prison. Am J Gastroenterol 2001;96:1304-1305.
    Direct Link:
  • 13
    Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012;55(Suppl 1):S33-S42.
  • 14
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2012;54:1433-1444.
  • 15
    Gane E. Future perspectives: towards interferon-free regimens for HCV. Antiviral Ther 2012;17:1201-1210.
  • 16
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA Statement. PLoS Med 2009;6:e1000097.
  • 17
    Gough E, Kempf MC, Graham L, Manzanero M, Hook EW, Bartolucci A, HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health 2010;10:art. no. 777.
  • 18
    Macalino GE, Hou JC, Kumar MS, Taylor LE, Sumantera IG, Rich JD. Hepatitis C infection and incarcerated populations. Int J Drug Policy 2004;15:103-114.
  • 19
    Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Commun Health 2008;62:305-313.
  • 20
    Stern RK, Hagan H, Lelutiu-Weinberger C, Des Jarlais D, Scheinmann R, Strauss S, et al. The HCV Synthesis Project: scope, methodology and preliminary results. BMC Med Res Methodol 2008;8:62.
  • 21
    Ali H, Calabria B, Phillips B, Singleton J, Sigmundsdottir L, Congreve E, et al. Searching the grey literature to access information on drugs, alcohol and HIV/AIDS research: an update. Sydney: National Drug and Alcohol Research Centre; 2010.
  • 22
    WHO. Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Vietnam: an application of selected human rights principles. Manila: World Health Organization Western Pacific Regional Office; 2009.
  • 23
    Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. metan: fixed- and random-effects meta-analysis. Stata J 2008;8:3-28.
  • 24
    Harbord RM, Higgins JPT. Meta-regression in Stata. Stata J 2008;8:493-519.
  • 25
    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557-560.
  • 26
    Hagan H, Pouget ER, Des Jarlais D, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008;168:1099-1109.
  • 27
    Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon. J Infect Dev Countries 2010;4:144-149.
  • 28
    Chu F-Y, Chiang S-C, Su F-H, Chang Y-Y, Cheng S-H. Prevalence of human immunodeficiency virus and its association with hepatitis B, C, and D virus infections among incarcerated male substance abusers in Taiwan. J Med Virol 2009;81:973-978.
  • 29
    Kheirandish P, Seyedalinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health 2009;86:902-908.
  • 30
    Popov GT, Plochev KS, Chervenyakova TP. Prevalence of hepatitis C virus infection among juvenile prisoners. J Hepatol 2012;56:S546.
  • 31
    Ogilvie EL, Veit F, Crofts N, Thompson SC. Hepatitis infection among adolescents resident in Melbourne Juvenile Justice Centre: risk factors and challenges. J Adolesc Health 1999;25:46-51.
  • 32
    Walmsley R. World prison population list, 9th ed. 2011., accessed November 2012.
  • 33
    Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011;20:474-483.
  • 34
    WHO. Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: World Health Organization; 2012.
  • 35
    Jurgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 2009;9:57-66.
  • 36
    Larney S, Toson B, Burns L, Dolan K. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction 2012;107:372-380.
  • 37
    WHO. Interventions to address HIV in prisons: needle and syringe programmes and decontamination strategies. Geneva: World Health Organization; 2007.
  • 38
    Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res 2009;15:107-112.
  • 39
    Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treatment of acute hepatitis C virus infection. Infect Dis Clin N Am 2012;26.
  • 40
    Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003;138:187-190.
  • 41
    Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust 2010;192:496-500.
  • 42
    United Nations. Joint statement: compulsory drug detention and rehabilitation centres. Available from:, accessed March 5, 2013: United Nations; 2012.